A weight loss drug that mimics Ozempic will be available from pharmacies from next week after a two-year delay.

The sister drug of Ozempic, Wegovy – which is made by the same company, was given the green light to be marketed as a chronic weight management drug two years ago.

Supply issues caused delays in its launch in Australia, but the drug will now be available from Monday.

A weight loss drug that mimics Ozempic will be available from pharmacies from next week after a two-year delay. (Nine)

Experts say weight loss drugs have multiple health benefits.

“We’re seeing medications such as Wegovy having multiple benefits beyond weight loss,” Obesity Specialist Dr Georgia Rigas said.

“The main thing is we’re seeing improvements in blood pressure, heart disease, kidney function [and] fertility.”

Wegovy claims to work the same way as Ozempic, mimicking the natural hormone GLP-1 to control hunger, however, the weekly dosage for Wegovy is higher.

Experts say weight loss drugs have multiple health benefits. (Nine)

The recommended monthly dose on a private prescription will cost customers about $460.

The drug is meant to be used in combination with a good diet and exercise, experts say.

To be eligible for a prescription patients need to be overweight or obese, with at least one complication linked to the disease.

Attempts to have Wegovy subsidised through the PBS have been unsuccessful.

You May Also Like

Frantic mayday call revealed chaos after deadly Florida ferry boat collision: ‘Ferry is adrift’

Newly released audio of a mayday call captured the frantic moments in…

Police smelled a 'dead body' inside accused murderer's tool box, court hears

A detective immediately smelled a dead body when she opened a large…

Four dead, including children, after car crashes into after-school camp

Four people are dead, including children, and several others are injured after…

Giants clap back at Donald Trump’s story of Saquon Barkley warning: ‘Stop yapping’

The Giants are pushing back on President Donald Trump’s claim that he…